{"address1": "An der Goldgrube 12", "city": "Mainz", "zip": "55131", "country": "Germany", "phone": "49 6131 9084", "fax": "49 6131 9084", "website": "https://www.biontech.de", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.", "fullTimeEmployees": 6772, "companyOfficers": [{"maxAge": 1, "name": "Dr. Ugur  Sahin M.D.", "age": 59, "title": "Co-Founder, CEO & Chair of the Management Board", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 1043937, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ozlem  Tureci M.D.", "age": 57, "title": "Co-Founder, Chief Medical Officer & Member of Management Board", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 835150, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jens H. Holstein", "age": 61, "title": "CFO & Member of Management Board", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 840559, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sierk  Poetting Ph.D.", "age": 51, "title": "MD, COO & Member of Management Board", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 855704, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan  Richardson", "age": 45, "title": "Chief Strategy Officer, MD & Member of Management Board", "yearBorn": 1979, "fiscalYear": 2024, "totalPay": 864358, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James Timothy Patrick Ryan Ph.D.", "age": 49, "title": "Chief Legal & Business Officer & Member of the Management Board", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 953066, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Annemarie  Hanekamp", "age": 44, "title": "Chief Commercial Officer & Member of Management Board", "yearBorn": 1980, "fiscalYear": 2024, "totalPay": 1868269, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Lisa  Birringer", "title": "Senior Vice President of Global Financial Reporting & Accounting", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Zach  Taylor", "title": "Senior Vice President of Corporate Development & Strategy", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Beate  Berns", "title": "Senior Vice President of Global Human Resources", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 4, "compensationRisk": 6, "shareHolderRightsRisk": 1, "overallRisk": 4, "governanceEpochDate": 1743465600, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 90.29, "open": 89.27, "dayLow": 88.78, "dayHigh": 94.235, "regularMarketPreviousClose": 90.29, "regularMarketOpen": 89.27, "regularMarketDayLow": 88.78, "regularMarketDayHigh": 94.235, "exDividendDate": 1654128000, "payoutRatio": 0.0, "beta": 0.308, "forwardPE": -23.928204, "volume": 1222843, "regularMarketVolume": 1222843, "averageVolume": 847985, "averageVolume10days": 1040850, "averageDailyVolume10Day": 1040850, "bid": 93.09, "ask": 93.5, "bidSize": 6, "askSize": 2, "marketCap": 22394093568, "fiftyTwoWeekLow": 76.53, "fiftyTwoWeekHigh": 131.49, "priceToSalesTrailing12Months": 8.140051, "fiftyDayAverage": 109.9245, "twoHundredDayAverage": 104.69913, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 5137563648, "profitMargins": -0.24183, "floatShares": 92355164, "sharesOutstanding": 239971008, "sharesShort": 3217746, "sharesShortPriorMonth": 3015369, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.0134000005, "heldPercentInsiders": 0.63229, "heldPercentInstitutions": 0.21936001, "shortRatio": 3.53, "shortPercentOfFloat": 0.035, "impliedSharesOutstanding": 250222000, "bookValue": 80.889, "priceToBook": 1.1536797, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "earningsQuarterlyGrowth": -0.433, "netIncomeToCommon": -665299968, "trailingEps": -3.0, "forwardEps": -3.9, "enterpriseToRevenue": 1.867, "enterpriseToEbitda": -4.973, "52WeekChange": 0.03758061, "SandP52WeekChange": 0.101756096, "lastDividendValue": 2.111, "lastDividendDate": 1654128000, "quoteType": "EQUITY", "currentPrice": 93.32, "targetHighPrice": 172.04585, "targetLowPrice": 110.86463, "targetMeanPrice": 138.79706, "targetMedianPrice": 141.10043, "recommendationMean": 1.59091, "recommendationKey": "buy", "numberOfAnalystOpinions": 21, "totalCash": 16783599616, "totalCashPerShare": 69.94, "ebitda": -1033100032, "totalDebt": 254200000, "quickRatio": 7.256, "currentRatio": 7.452, "totalRevenue": 2751099904, "debtToEquity": 1.31, "revenuePerShare": 11.444, "returnOnAssets": -0.03529, "returnOnEquity": -0.03355, "grossProfits": 2209799936, "freeCashflow": 534987488, "operatingCashflow": 207700000, "earningsGrowth": -0.432, "revenueGrowth": -0.195, "grossMargins": 0.80324, "ebitdaMargins": -0.37552, "operatingMargins": 0.13319, "financialCurrency": "EUR", "symbol": "BNTX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1743638035, "regularMarketTime": 1743624001, "exchange": "NMS", "messageBoardId": "finmb_51198843", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 3.3558521, "regularMarketPrice": 93.32, "earningsTimestampStart": 1746448200, "earningsTimestampEnd": 1746448200, "earningsCallTimestampStart": 1746442740, "earningsCallTimestampEnd": 1746442740, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -3.0, "epsForward": -3.9, "epsCurrentYear": -4.92615, "priceEpsCurrentYear": -18.9438, "fiftyDayAverageChange": -16.6045, "fiftyDayAverageChangePercent": -0.15105368, "twoHundredDayAverageChange": -11.3791275, "twoHundredDayAverageChangePercent": -0.10868407, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.6 - Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1570714200000, "postMarketChangePercent": -1.54308, "postMarketPrice": 91.88, "postMarketChange": -1.44, "regularMarketChange": 3.0299988, "regularMarketDayRange": "88.78 - 94.235", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 847985, "fiftyTwoWeekLowChange": 16.79, "fiftyTwoWeekLowChangePercent": 0.21939111, "fiftyTwoWeekRange": "76.53 - 131.49", "fiftyTwoWeekHighChange": -38.170006, "fiftyTwoWeekHighChangePercent": -0.29028827, "fiftyTwoWeekChangePercent": 3.758061, "dividendDate": 1655424000, "earningsTimestamp": 1746448200, "shortName": "BioNTech SE", "longName": "BioNTech SE", "marketState": "PREPRE", "trailingPegRatio": null}